AFYX Therapeutics Presents Results from Rivelin Clinical Proof of Concept Study in Patients with Vulvar Lichen Sclerosus at the 2019 European Academy of Dermatology and Venereology Congress

By In The News
October 9, 2019 in The Headlines

Recommended Posts

In The News

Posted October 9, 2019

- Share

Posted October 9, 2019

SAN DIEGO and COPENHAGEN, Denmark, Oct. 9, 2019 /PRNewswire/ -- AFYX Therapeutics, a clinical stage biopharmaceutical company developing innovative approaches to treat mucosal diseases, today announced results from a Phase 1 clinical proof of concept study evaluating the use of the...

View the full article

Link to comment

Share on other sites

Archived

This topic is now archived and is closed to further replies.

Go to topic listing

Most Contributions
1. In The News
  219920
2. Jaydee
  16805
3. Kip Powick
  12216
4. deicer
  12196
5. dagger
  9595
Tell a friend
Love The Airline Website? Tell a friend!
- Email
- Share
Forum Statistics
- Total Topics
  
  270.2k
- Total Posts
  
  558.8k

Sign In

AFYX Therapeutics Presents Results from Rivelin Clinical Proof of Concept Study in Patients with Vulvar Lichen Sclerosus at the 2019 European Academy of Dermatology and Venereology Congress

Recommended Posts

In The News

Link to comment

Share on other sites

Archived

Most Contributions

Tell a friend

Forum Statistics

Browse

Activity

Support